Lyl273

Preclinical

LLyell Immunopharma, Inc.

Lyl273 is one of 49 therapeutic programs targeting Colorectal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Colorectal CancerRecruiting

Colorectal CancerPreclinical

Recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

25 2

Fudr

Pfizer

Phase 3

17 3

Tecentriq

Roche

Phase 3

6 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

5-Fu

TToray Industries, Inc

Phase 3

4 7

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 8

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 9

HR070803

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

PreclinicalRecruiting

Colorectal Cancer

NCT05319314

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer

Recruiting·LLyell Immunopharma, Inc.·Preclinical·NCT05319314·155 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lyl273. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lyl273. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lyell Immunopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: LLyell Immunopharma, Inc.

Lyl273

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News